Medifast (NYSE:MED) Shares Cross Above 200 Day Moving Average – Here’s What Happened

Medifast Inc (NYSE:MED)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $11.16 and traded as high as $12.45. Medifast shares last traded at $12.2950, with a volume of 112,614 shares traded.

Wall Street Analysts Forecast Growth

MED has been the subject of several recent analyst reports. Weiss Ratings cut shares of Medifast from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Wall Street Zen upgraded Medifast from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Finally, Stephens reduced their target price on Medifast from $15.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, February 19th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $12.00.

Medifast Stock Performance

The stock’s 50 day simple moving average is $11.46 and its 200 day simple moving average is $11.16. The firm has a market cap of $136.72 million, a PE ratio of -6.72 and a beta of 0.62.

Medifast (NYSE:MED) last issued its quarterly earnings results on Monday, May 4th. The specialty retailer reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.36. The firm had revenue of $76.04 million during the quarter, compared to analyst estimates of $69.20 million. Medifast had a negative return on equity of 4.80% and a negative net margin of 5.78%.Medifast has set its FY 2026 guidance at -2.750–1.550 EPS and its Q2 2026 guidance at -1.000–0.500 EPS. As a group, analysts anticipate that Medifast Inc will post -1.97 earnings per share for the current year.

Insider Buying and Selling

In other Medifast news, Director Scott Schlackman acquired 2,500 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $12.53 per share, with a total value of $31,325.00. Following the purchase, the director owned 30,549 shares of the company’s stock, valued at approximately $382,778.97. This trade represents a 8.91% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Daniel R. Chard bought 17,678 shares of Medifast stock in a transaction that occurred on Friday, March 20th. The shares were acquired at an average cost of $10.11 per share, for a total transaction of $178,724.58. Following the acquisition, the chief executive officer owned 17,678 shares in the company, valued at $178,724.58. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 22,678 shares of company stock worth $241,675 over the last quarter. Company insiders own 3.70% of the company’s stock.

Institutional Trading of Medifast

Several hedge funds have recently added to or reduced their stakes in the business. Amundi boosted its position in Medifast by 43.5% during the first quarter. Amundi now owns 30,439 shares of the specialty retailer’s stock valued at $398,000 after buying an additional 9,224 shares during the period. AQR Capital Management LLC increased its holdings in shares of Medifast by 14.5% in the first quarter. AQR Capital Management LLC now owns 199,750 shares of the specialty retailer’s stock worth $2,693,000 after buying an additional 25,366 shares during the period. Strs Ohio bought a new stake in shares of Medifast in the 1st quarter valued at about $78,000. JPMorgan Chase & Co. boosted its holdings in Medifast by 2.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 53,341 shares of the specialty retailer’s stock valued at $749,000 after acquiring an additional 1,316 shares during the period. Finally, Prudential Financial Inc. purchased a new stake in Medifast during the 2nd quarter valued at about $200,000. 95.51% of the stock is owned by institutional investors.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.